WS Investor
12 Aug 2026, 16:10
BD Completes Enrollment in Landmark Phasix Mesh Hernia Prevention Trial
Becton, Dickinson and Company (NYSE: BDX) has completed patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for the prevention of incisional hernias following abdominal surgery.
The randomized study enrolled 477 patients across 32 sites in the U.S. and Europe. According to BD, it is the first large-scale randomized trial evaluating prophylactic incisional hernia prevention using a resorbable mesh.
The trial targets patients at high risk of developing incisional hernias following elective open midline abdominal surgery. The milestone supports BD's strategy to expand its advanced tissue regeneration technologies into new clinical applications.
Patients will be followed through the trial's primary endpoint at 24 months, with additional follow-up planned for up to five years to assess safety and clinical outcomes.
If the study produces supportive results, BD expects the data to form part of a planned FDA submission seeking authorization for Phasix Mesh in this new indication.
The program could represent an important expansion opportunity for BD's surgical portfolio, as the company noted that no products are currently approved specifically for preventing incisional hernias following abdominal surgery.
Becton, Dickinson and Company (NYSE: BDX) has completed patient enrollment in its PREVENT clinical trial evaluating Phasix Mesh for the prevention of incisional hernias following abdominal surgery.
The randomized study enrolled 477 patients across 32 sites in the U.S. and Europe. According to BD, it is the first large-scale randomized trial evaluating prophylactic incisional hernia prevention using a resorbable mesh.
The trial targets patients at high risk of developing incisional hernias following elective open midline abdominal surgery. The milestone supports BD's strategy to expand its advanced tissue regeneration technologies into new clinical applications.
Patients will be followed through the trial's primary endpoint at 24 months, with additional follow-up planned for up to five years to assess safety and clinical outcomes.
If the study produces supportive results, BD expects the data to form part of a planned FDA submission seeking authorization for Phasix Mesh in this new indication.
The program could represent an important expansion opportunity for BD's surgical portfolio, as the company noted that no products are currently approved specifically for preventing incisional hernias following abdominal surgery.
